| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The expression of miR/isomiR in sera collected from esophageal squamous cell carcinoma patients (ESCC) and healthy control (HC) treated at our hospital was investigated by next-generation sequencing. These cases were divided into two groups, and diagnostic biomarkers were defined as those that were detectable in more than 90% of cases and that differed more than two-fold in the mean number of reads in predominance, and reproducibility between the two groups was confirmed. As a result, one mature miR(X) and two isomiRs(Y and Z) were selected in multivariate linear regression analysis. These diagnostic panel indices were significantly higher in ESCC cases than in HC and significantly lower in esophageal adenocarcinoma and highly atypical cases than in the ESCC group.(At present, the name of miR / isomiR are anonymous.)
|
